Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2021
- Application to initiate clinical trial of HDP-101 green-lighted by the FDA in February 2021
- Management team expanded
- New financing commitment for up to EUR 30 million obtained from main shareholder dievini
- New preclinical data from the ATAC technology platform presented at the AACR 2021 Annual Meeting
Heidelberg Pharma AG today reported on the first three months of fiscal year 2021 (1 December 2020 – 28 February 2021) and the Group’s financial figures.